ADCs are designed to deliver chemotherapy directly to tumours. However, more than 95% of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
